Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.
Hanson A, Elpek K, Duong E, Shallberg L, Fan M, Johnson C, Wallace M, Mabry GR, Sazinsky S, Pepper L, Shu CJ, Sathyanarayanan S, Zuerndorfer S, Simpson T, Gostissa M, Briskin M, Law D, Michaelson J, Harvey CJ. Hanson A, et al. Among authors: gostissa m. PLoS One. 2020 Sep 24;15(9):e0239595. doi: 10.1371/journal.pone.0239595. eCollection 2020. PLoS One. 2020. PMID: 32970735 Free PMC article.
Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
Weaver JD, Stack EC, Buggé JA, Hu C, McGrath L, Mueller A, Wong M, Klebanov B, Rahman T, Kaufman R, Fregeau C, Spaulding V, Priess M, Legendre K, Jaffe S, Upadhyay D, Singh A, Xu CA, Krukenberg K, Zhang Y, Ezzyat Y, Saddier Axe D, Kuhne MR, Meehl MA, Shaffer DR, Weist BM, Wiederschain D, Depis F, Gostissa M. Weaver JD, et al. Among authors: gostissa m. Oncoimmunology. 2022 Nov 4;11(1):2141007. doi: 10.1080/2162402X.2022.2141007. eCollection 2022. Oncoimmunology. 2022. PMID: 36352891 Free PMC article.
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors.
Umiker B, Hashambhoy-Ramsay Y, Smith J, Rahman T, Mueller A, Davidson R, Meyer C, Patankar G, Alam MM, Jaffe S, Krukenberg K, Goodman A, Spaulding V, Priess M, Dhaneshwar A, Wong M, Diiorio A, O'Malley K, McGrath L, Willer M, Pepper L, Gostissa M, Kis-Toth K, Wiederschain D, Cohen H, Shaffer DR. Umiker B, et al. Among authors: gostissa m. Mol Cancer Ther. 2023 Apr 3;22(4):471-484. doi: 10.1158/1535-7163.MCT-22-0351. Mol Cancer Ther. 2023. PMID: 36780212
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R. Compagno M, et al. Among authors: gostissa m. Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15. Nature. 2017. PMID: 28199309 Free PMC article.
43 results